BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34076966)

  • 1. Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
    Tanaka H; Hasegawa Y; Fujita Y; Nakamura A; Kikuchi E; Kawai Y; Harada T; Watanabe N; Yokouchi H; Usui K; Saito R; Watanabe H; Masuda T; Fukuhara T; Kudo K; Honda R; Oizimi S; Maemondo M; Inoue A; Morikawa N
    Thorac Cancer; 2021 Jul; 12(14):2113-2121. PubMed ID: 34076966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
    Satouchi M; Kotani Y; Shibata T; Ando M; Nakagawa K; Yamamoto N; Ichinose Y; Ohe Y; Nishio M; Hida T; Takeda K; Kimura T; Minato K; Yokoyama A; Atagi S; Fukuda H; Tamura T; Saijo N
    J Clin Oncol; 2014 Apr; 32(12):1262-8. PubMed ID: 24638015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
    BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
    Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
    Han JY; Kim HT; Lim KY; Yoon SJ; Lee DH; Lee JS
    J Thorac Oncol; 2008 Sep; 3(9):1039-45. PubMed ID: 18758308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
    Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
    Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
    Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
    Kim DW; Kim HG; Kim JH; Park K; Kim HK; Jang JS; Kim BS; Kang JH; Lee KH; Kim SW; Ryoo HM; Kim JS; Lee KH; Kwon JH; Choi JH; Shin SW; Hahn S; Heo DS
    Cancer Res Treat; 2019 Jan; 51(1):119-127. PubMed ID: 29529858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
    Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
    Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
    Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
    J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
    Shimokawa T; Okamoto H; Machida R; Misumi Y; Hosomi Y; Yoneshima Y; Tanaka H; Okishio K; Simizu J; Goto K; Akamatsu H; Kubota K; Nakagawa K; Horinouchi H; Ando M; Kataoka T; Ohe Y
    Lung Cancer; 2023 Jul; 181():107195. PubMed ID: 37156212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.